Full Text View
Tabular View
No Study Results Posted
Related Studies
FTY720 in Patients With Primary Progressive Multiple Sclerosis (INFORMS)
This study is ongoing, but not recruiting participants.
Study NCT00731692   Information provided by Novartis
First Received: August 7, 2008   Last Updated: November 16, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
Placebo
FTY720D 1.25mg
Additional drug interventions recognized in this trial
Fingolimod
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services